Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

MustGrow Announces Record Q3-2025 Results

By The Northwire Desk — AI Analysis Nov 25, 2025 · 16:01 MGRO · 0.56 MustGrow Biologics Corp.
MGRO · Price

Executive Summary

  • MustGrow Biologics reported Q3‑2025 sales of $0.8 M, up from zero in the same quarter last year, with a gross profit of $180,555 and a 22.9% gross margin.
  • Cash and cash equivalents stood at $3.3 M as of September 30 2025, alongside inventory of $1.9 M.
  • Management highlighted improved margins from higher‑margin product sales through NexusBioAg and expressed confidence in stronger Q4‑2025 and Q1‑2026 performance.

Key Details

  • Revenue: $0.8 million for the three months ended September 30 2025 (vs. $0 in Q3‑2024).
  • Gross Profit: $180,555, representing a 22.9% gross profit margin (up from 20.9% in Q2‑2025).
  • Cash Position: $3.3 million cash and cash equivalents on hand at quarter end.
  • Inventory: $1.9 million recorded as of September 30 2025.
  • Margin Commentary: Gross margin improvement attributed to higher‑margin product sales via the Canadian NexusBioAg distribution channel.
  • Seasonality Note: Q3 is traditionally a low‑revenue “shoulder season” for Canadian agriculture; stronger sales are expected in Q4 and Q1‑2026 as farmers prepare for the next growing season.
  • Strategic Focus: Continued capital allocation toward revenue growth of NexusBioAg (Canadian distribution) and TerraSante™ biofertility products (U.S. market).

Notable Quotes

“The third calendar quarter is typically the lowest product revenue ‘shoulder season’ for Canadian agriculture… We are looking forward to a strong finish to the year in Q4 and also Q1‑2026 as farmers purchase products in preparation for the 2026 growing season.” – Corey Giasson, President & CEO

Materiality Assessment: Material – Positive (earnings release with revenue generation and positive margin trend).

Read the original news release →

More from MustGrow Biologics Corp.

Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other